Berry Genetics (000710): Net profit in 2020 is 200 million, a year-on-year increase of -46.07%. Berry Genetics has developed into an industrial structure headquartered in Beijing, covering medical laboratories in Shanghai, Qingdao, Chengdu, Changsha, Hangzhou and Hangzhou production bases. In Hong Kong, Berry Genetics has cooperated with Professor Lu Yuming of the Chinese University of Hong Kong to establish Hong Kong Xcelom Gene Technology Co., Ltd. (Xcelom) relies on the patent authorization of the Chinese University of Hong Kong to provide more secure genetic testing services to Hong Kong and surrounding areas.
Aide Biotechnology (300685): Net profit in 2020 is 180 million, a year-on-year increase of 33.11%. Relying on its PCR technology platform with independent intellectual property rights, the company has developed a new coronavirus genetic detection kit and is applying to enter the emergency approval channel opened by the State Food and Drug Administration for this epidemic.
Dirui Medical (300396): The company’s net profit in 2020 was 267 million yuan, a year-on-year increase of 15.17%. The company's existing products have passed the EU CE safety certification, related products have passed the US FDA certification, the company's testing center has been accredited by CNAS, and the management system has passed ISO9001, ISO13485 international quality system and QC080000 hazardous substance process management system certification.
Meikang Biological (300439): Net profit in 2020 is 300 million. In February 2020, the company recently completed the research and development of a new coronavirus nucleic acid detection kit and a new coronavirus protein rapid detection kit, which are still in the company's clinical verification stage. The results of the clinical verification meet the relevant testing standards. The company will submit samples and related Apply for registration with the National Medical Products Administration.
In April 2020, the company’s new coronavirus 2019-nCoV antibody (IgM/IgG) joint detection kit (latex method) and new coronavirus 2019-nCoV nucleic acid detection kit (fluorescence PCR method) were both It complies with the EU In Vitro Diagnostic Device Directive 98/79/EC and has obtained the EU CE certification.
Xinbang Pharmaceutical (002390): Net profit in 2020 was RMB 174 million, a year-on-year increase of -26.57%.
The data is for reference only and does not constitute investment advice. Operations based on this information are at your own risk. There are risks in the stock market, so investment needs to be cautious.